Congestive Heart Failure Clinical Trial
Official title:
A Phase 2, Double-Blind, Randomized, Safety Study of GE-145 320 mg I/mL Injection Versus Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Artery Catheterization Procedure
Verified date | August 2018 |
Source | GE Healthcare |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To evaluate cardio-renal and overall safety profile of GE 145 320 mg I/ml Injection when compared to iopamidol 370 mg I/mL. The study will focus on elderly subjects with either chronic renal insufficiency, or diabetes mellitus (DM) requiring drug therapy, or congestive heart failure (CHF) NYHA Class III or greater, who are referred for a coronary catheterization procedure with or without PCI.
Status | Completed |
Enrollment | 284 |
Est. completion date | December 2012 |
Est. primary completion date | December 2012 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 65 Years and older |
Eligibility |
Inclusion Criteria: - Males and females 65 years of age with cardiovascular disease who are referred for a coronary catheterization procedure with or without PCI. - The subject has at least one of the following comorbidities: - 1) Chronic renal insufficiency, (eGFR <60 but 15 mL/min/1.73 m2 according to the MDRD equation) as measured within 2 weeks or at the screening visit; - 2) DM diagnosed greater than 6 months prior to study entry and which requires either insulin or anti-hyperglycemic drug therapy; - 3) CHF (NYHA) class III or greater measured within 2 weeks of enrollment or at the screening visit. Exclusion Criteria: - The subject has known allergies to either iodine or any ICM. - The subject has severe renal insufficiency (eGFR <15 mL/min/1.73 m2 according to the MDRD equation) or is on dialysis. - The subject has acute coronary syndrome requiring emergency coronary angiography and/or intervention. - The subject is not willing or unable to discontinue metformin (e.g., Glucophage) at the time of the study procedure. |
Country | Name | City | State |
---|---|---|---|
United States | GE Healthcare | Princeton | New Jersey |
Lead Sponsor | Collaborator |
---|---|
GE Healthcare | Biomedical Systems, i3 Statprobe, Medpace, Inc., Rules-Based Medicine, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Comparison of Overall Image Quality Between Ioforminol and Iopamidol-enhanced Images as Determined by an Independent Reader. | Overall image quality (excellent, adequate or poor) and diagnostic usefulness (diagnostic or non-diagnostic) were assessed using qualitative scales. | After the imaging date for either Ioforminol or Iopamidol. | |
Secondary | To Determine Incidence Rates of the Overall AEs, Organ-specific AEs (i.e., Delayed Skin Reactions, General Subject Comfort, and Allergic/Immunologic Reactions, Etc.) and SAEs Following Administration | To determine incidence rates of the overall AEs, organ-specific AEs (i.e., delayed skin reactions, general subject comfort, and allergic/immunologic reactions, etc.) and SAEs following administration of GE-145 or iopamidol. To determine incidence rates and onset time of biomarker-based and SCr-based CI-AKI following administration of GE-145 or iopamidol. Summary of Treatment-Emergent Adverse Events (TEAE) in greater than of equal to 2% of Subjects. |
Time zero equals the date of contrast imaging and for up to 7 days for safety monitoring post contrast administration. | |
Secondary | Assessing the Incidence of Renal Biomarker-based Contrast-induced Acute Kidney Injury (CI-AKI) in Subjects Post Administration of Ioforminol or Iopamidol Injections | Analyzing the number of subjects with renal biomarker-based contrast-induced acute kidney injury (CI-AKI). | 2, 6 and 24 hours post Ioforminol and Iopamidol adminstration |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04115735 -
His Bundle Recording From Subclavian Vein
|
||
Recruiting |
NCT05562037 -
Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA
|
N/A | |
Completed |
NCT05563701 -
Evaluation of the LVivo Image Quality Scoring (IQS)
|
||
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Completed |
NCT04037436 -
Functional Exercise and Nutrition Education Program for Older Adults
|
N/A | |
Recruiting |
NCT04703842 -
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
|
Phase 1/Phase 2 | |
Terminated |
NCT05594940 -
Heart Failure Monitoring With a Portable Ultrasound Device With Artificial Intelligence Assisted Tools: A Multi-Phase Observational Feasibility Study
|
||
Recruiting |
NCT04982081 -
Treating Congestive HF With hiPSC-CMs Through Endocardial Injection
|
Phase 1 | |
Completed |
NCT04394754 -
Evaluating Efficacy of Digital Health Technology in the Treatment of Congestive Heart Failure
|
N/A | |
Active, not recruiting |
NCT01385176 -
Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF)
|
N/A | |
Not yet recruiting |
NCT05516290 -
Evaluating Clinical Trial Experiences of Individuals With Congestive Heart Failure
|
||
Terminated |
NCT02788656 -
Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)
|
Phase 4 | |
Completed |
NCT02885636 -
Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial
|
Phase 3 | |
Terminated |
NCT02205411 -
Clinical Trial to Evaluate the the ReliantHeart HeartAssist 5® VAD System in Patients Awaiting Heart Transplantation
|
N/A | |
Completed |
NCT02252757 -
Assess Measurements of Wireless Cardiac Output Device
|
N/A | |
Completed |
NCT01362855 -
Advance Care Planning Evaluation in Hospitalized Elderly Patients
|
||
Withdrawn |
NCT00346177 -
Stem Cell Study for Patients With Heart Failure
|
Phase 2 | |
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Active, not recruiting |
NCT01058837 -
SCD-HeFT 10 Year Follow-up
|
N/A | |
Completed |
NCT00957541 -
Evaluation of a Diagnostic Feature in a Cardiac Resynchronization Therapy (CRT) Device
|
Phase 2 |